BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31292127)

  • 1. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.
    Miller J; Ross JS; Wilenzick M; Mello MM
    BMJ; 2019 Jul; 366():l4217. PubMed ID: 31292127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis.
    Axson S; Mello MM; Lincow D; Yang C; Gross C; Ross JS; Miller J
    BMJ Open; 2021 Jul; 11(7):e053248. PubMed ID: 34281933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
    Miller JE; Korn D; Ross JS
    BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration.
    Modi ND; Abuhelwa AY; McKinnon RA; Boddy AV; Haseloff M; Wiese MD; Hoffmann TC; Perakslis ED; Rowland A; Sorich MJ; Hopkins AM
    JAMA Oncol; 2022 Sep; 8(9):1310-1316. PubMed ID: 35900732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
    Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
    JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical companies' policies on access to trial data, results, and methods: audit study.
    Goldacre B; Lane S; Mahtani KR; Heneghan C; Onakpoya I; Bushfield I; Smeeth L
    BMJ; 2017 Jul; 358():j3334. PubMed ID: 28747301
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
    Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J
    BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation.
    Hopkins AM; Modi ND; Rockhold FW; Hoffmann T; Menz BD; Veroniki AA; McKinnon RA; Rowland A; Swain SM; Ross JS; Sorich MJ
    J Clin Epidemiol; 2024 Mar; 167():111263. PubMed ID: 38219810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
    Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
    JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data sharing from pharmaceutical industry sponsored clinical studies: audit of data availability.
    Hopkins AM; Rowland A; Sorich MJ
    BMC Med; 2018 Sep; 16(1):165. PubMed ID: 30261889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncommercial US Funders' Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability.
    Whitlock EP; Dunham KM; DiGioia K; Lazowick E; Gleason TC; Atkins D
    JAMA Netw Open; 2019 Jan; 2(1):e187498. PubMed ID: 30681715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of available studies and dissemination of research using major clinical data sharing platforms.
    Vazquez E; Gouraud H; Naudet F; Gross CP; Krumholz HM; Ross JS; Wallach JD
    Clin Trials; 2021 Dec; 18(6):657-666. PubMed ID: 34407656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement.
    Danchev V; Min Y; Borghi J; Baiocchi M; Ioannidis JPA
    JAMA Netw Open; 2021 Jan; 4(1):e2033972. PubMed ID: 33507256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
    Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
    JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
    Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
    BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
    Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
    BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2013.
    Deane BR; Sivarajah J
    Curr Med Res Opin; 2017 Mar; 33(3):473-478. PubMed ID: 27869482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
    Deane BR; Porkess S
    Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.